deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01571596

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

An Open-Label, Long-Term, Extension Study to Evaluate the Safety and Efficacy of KRN23 in Adult Subjects With X-Linked Hypophosphatemia

Sponsor: Kyowa Hakko Kirin Pharma, Inc.

Conditions X-linked Hypophosphatemia
Interventions KRN23
Updated 10 times since 2017 Last updated: Jun 14, 2024 Started: Feb 29, 2012 Primary completion: Sep 30, 2013 Completion: Jun 30, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on X-linked Hypophosphatemia, this trial is completed. The trial is conducted by Kyowa Hakko Kirin Pharma, Inc. and has accumulated 10 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshotCompleted~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotCompleted~Mar 2021 – ~Oct 2021 · 7 months · monthly snapshotCompleted~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Oct 2021 — Dec 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Mar 2021 — Oct 2021 [monthly]

    Completed PHASE1_PHASE2

▶ Show 5 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Completed PHASE1_PHASE2

  2. Aug 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Jun 2018 — Aug 2019 [monthly]

    Completed PHASE1_PHASE2

  4. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Kyowa Hakko Kirin Pharma, Inc.
  • Kyowa Kirin Co., Ltd.
Data source: Kyowa Kirin Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations